36C10G24R0013_1.docx

SUBJECT*

Copy of Tumor Molecular Testing Services

GENERAL INFORMATION

OPAL | Strategic Acquisition Center

10300 Spotsylvania Ave | STE 400 Fredericksburg VA 22408-2697

POINT OF CONTACT*

Contract Specialist Michelle Bailey michelle.bailey@va.gov 202-632-5417

PLACE OF PERFORMANCE

POSTAL CODE

COUNTRY

ADDITIONAL INFORMATION

AGENCY’S URL

URL DESCRIPTION

Combined Synopsis/Solicitation Notice Combined Synopsis/Solicitation Notice

DESCRIPTION

Combined Synopsis/Solicitation Notice

Description This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, “Streamlined Procedures for Evaluation and Solicitation for Commercial Items,” as supplemented with additional information included in this notice. This announcement constitutes the only solicitation Tumor Molecular Testing Service under 36C10G24R0013, and a written solicitation document is attached.

This solicitation is a Request for Proposals. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2023-06, The associated North American Industrial Classification System (NAICS) code for this procurement is 621511 Medical Laboratories, with a small business size standard of $35M.

All interested companies shall provide submit a proposal in response to the attached RFP document. The items that are being solicited are as follows;

Supplies

Solid Tumor Test (NGS)

Services The Strategic Acquisition Center, in support of Veterans Health Administration (VHA), National Precision Oncology Program is seeking to purchase to secure specialized, comprehensive reference laboratory-based tumor molecular profiling services for clinical care. Services should include test offerings spanning both solid and hematological malignancies using methods such as next generation sequencing (NGS) panels, NGS comprehensive genomic profiling (CGP) as well as complementary tests to support NGS such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for biomarkers such as PD-L1, MMR, HER2. all used to guide clinical care for Veterans with cancer. All services provided shall be in accordance with the costs, terms, and conditions of this contract .

Place of Performance

Postal Code

The award resulting from this solicitation will be made based on the best overall proposal that is determined to be the most beneficial to the Government (i.e., best value trade-off), price and non-price factors considered. FAR 2.101 defines best value as the “expected outcome of an acquisition that, in the Government’s estimation, provides the greatest overall benefit in response to the requirement.”

Non-Price Factors (listed in descending order of importance)

1. Technical Approach

2. Past Performance

3. Socio-economic Considerations; and

Price Factors

4. Price.

Non-price factors when combined are significantly more important than price. The following non-price factors are listed in descending order of importance: Technical Approach, Past Performance and Socio-economic Considerations. It should be noted that award might be made to other than the lowest priced offeror if the Government determines that a price premium is warranted due to merits of one or more of the non-price factors.

The full text of FAR provisions or clauses may be accessed electronically at http://acquisition.gov/comp/far/index.html.

The following solicitation provisions apply to this acquisition:

1. FAR 52.212-1, “Instructions to Offerors–Commercial Items” June 2020]

2. FAR 52.212-2, “Evaluation – Commercial Items” October 2014

3. FAR 52.212-3, “Offerors Representations and Certifications–Commercial Items” November 2020

Offerors must complete annual representations and certifications on-line at http://orca.bpn.gov in accordance with FAR 52.212-3, “Offerors Representations and Certifications–Commercial Items.” If paragraph (j) of the provision is applicable, a written submission is required.

The following contract clauses apply to this acquisition:

· FAR 52.212-4, “Contract Terms and Conditions–Commercial Items” October 2018

· FAR 52.212-5, “Contract Terms and Conditions Required to Implement Statutes or Executive Orders” November 2020

All applicable clauses for this solicitation are stated in the attached RFP.

Point of Contact Michelle Bailey, michelle.bailey@va.gov Zachary Wilcox, Zachary.wilcox@va.gov

See attached document: RFP 36C10G24R0013 Tumor Molecular Testing.

See attached document: Appendix A_data format for Tumor Molecular Profiling_12.22.22_FINAL.

See attached document: Appendix B_Required Operational Fields_12.22.22_FINAL.

See attached document: Attachment 1 Invoice Inquiry Tracker.

See attached document: Attachment 2 Contractor Discrepancy Report.

See attached document: Attachment 3 - Excel Price-Cost Schedule 36C10G24R0013 Tumor Molecular Testing.

See attached document: Attachment 4 Pay.gov Vendor Submittal Instructions.

See attached document: Attachment 5 - HIPAA-Business Associate Agreement Tumor molecular profiling services.

See attached document: Attachment 6- Question Submission Format.

See attached document: Attachment 7 - Past Performance Questionnaire.

See attached document: There is no Attachment 8.

See attached document: Attachment 9 Quarterly Reporting Tool.

Page 1 of